JAK2 and acute lymphoblastic leukemia: Consistent with this, the JAK2 and BCL6 inhibition with ruxolitinib and FX1 prolonged the survival of xenograft models of CRLF2-r cell lines and CRLF2-r ALL patient-derived cells beyond that observed in mice treated with ruxolitinib or FX1 monotherapy [32].